ArticleFrontiers in oncology2025
Simultaneous double primary malignant tumors of MSS/pMMR ascending colon cancer and MSI-H/dMMR duodenal cancer with nearly 2 years of recurrence-free survival after MDT-guided comprehensive treatment: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role and synergistic mechanisms of clinical nurse specialists in cancer multidisciplinary treatment in China: a narrative review.Frontiers in psychology · 2026Review
- Immune Checkpoint Inhibition as a Novel Strategy for Microsatellite Instability-High Duodenal Adenocarcinoma: A Report of Three Cases.Surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exceedingly rare clinical presentation of synchronous ascending colon carcinoma with duodenal adenocarcinoma demonstrating discordant mismatch repair protein expression patterns forms the cornerstone of this investigation. Through detailed analysis of a unique case featuring co-occurring MSS/pMMR ascending colon adenocarcinoma and MSI-H/dMMR duodenal adenocarcinoma, this study demonstrates the successful implementation of multidisciplinary therapeutic protocols achieving 22-month progression-free survival post-radical resection. These clinical findings offer empirical evidence for optimizing clinical management while systematically addressing diagnostic complexities and treatment dilemmas inherent to synchronous dual primary intestinal carcinomas. Particular emphasis is placed on reconciling therapeutic conflicts arising from differential tumor biology and developing precision strategies for molecularly heterogeneous synchronous malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.